MDxHealth to Shut Down Resolve UTI Business
MDxHealth SA said it will discontinue its Resolve mdx urinary tract infection test and close its Plano, Texas lab, citing reimbursement challenges after Novitas Solutions reversed a Medicare policy, making continued operation “unsustainable,” according to the company. MDxHealth is contesting a $10.4 million recoupment decision. The move lowers 2026 revenue guidance to $110–$115 million from $137–$140 million.
How this was made
The 30-second read
Why it matters
A Medicare administrator policy reversal (Novitas Solutions) made continued Resolve operations “unsustainable,” prompting a planned shutdown and a 2026 revenue guidance reduction. The company is contesting a $10.4M recoupment decision via Medicare appeals, which could be a catalyst if outcomes improve.
Market read
Resolve shutdown and guidance cut are direct earnings-risk events for MDxHealth, with an additional overhang from the pending Medicare recoupment appeal.
What to watch
The article notes cash of $43.2M and that tissue-based tests (Confirm mdx, GPS mdx) drive most Q1 sales; these could cushion the revenue impact versus the market’s initial reaction.
Background
MDxHealth launched Resolve in 2021 and uses PCR to identify urinary organisms with results in 24–48 hours; the company is also integrating Exosome Diagnostics’ ExoDx Prostate test acquired last September.
Ticker impact
MDxHealth will shut down its Resolve UTI PCR test and Plano lab by end-June after Medicare reimbursement policy reversal by Novitas Solutions.
Bearish bias with elevated volatility; downside risk until appeals/transition execution clarity improves.
The article cites a 48% early-month share plunge, a lowered 2026 revenue range, and an operational shutdown tied to reimbursement changes, all of which directly affect MDxHealth’s earnings power.
Market effects
Highlights reimbursement-policy risk for molecular diagnostics and PCR-based lab tests, potentially pressuring investor sentiment across similar Medicare-exposed diagnostics.
Plano, Texas lab closure may reduce local operational footprint, but the broader read-through is limited beyond the company.
Primarily US reimbursement-driven; could influence global diagnostics investors’ risk models for US Medicare reimbursement dependence.
Counterpoint
If the Medicare recoupment appeal succeeds and the company executes a clean transition to its prostate cancer menu, the market may be over-discounting the longer-term earnings base.
Key entities
- companyMDxHealth SA
Will discontinue Resolve UTI test and close Plano lab by end-June; lowered 2026 revenue guidance and is appealing a $10.4M recoupment decision.
- regulator_adminNovitas Solutions
Medicare administrator whose policy reversal drove the company’s decision to exit Resolve operations.
- companyBio-Techne Ltd.
Acquired Exosome Diagnostics unit that MDxHealth later integrated, adding ExoDx Prostate to its portfolio.
